You have full text access to this OnlineOpen article

Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma

  1. M. Van Den Berge1,
  2. B. Luijk2,
  3. P. Bareille3,
  4. N. Dallow3,
  5. D. S. Postma2,
  6. J. -W. J. Lammers1,†

Article first published online: 29 OCT 2010

DOI: 10.1111/j.1398-9995.2010.02414.x

Issue

Allergy

Allergy

Volume 65, Issue 12, pages 1531–1535, December 2010

Additional Information

How to Cite

Van Den Berge, M., Luijk, B., Bareille, P., Dallow, N., Postma, D. S. and Lammers, J. .-W. J. (2010), Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy, 65: 1531–1535. doi: 10.1111/j.1398-9995.2010.02414.x

Author Information

  1. 1

    Department of Pulmonary Diseases, University Medical Center Groningen, The Netherlands

  2. 2

    Department of Pulmonary Diseases, Division of Heart and Lungs, University Medical Center Utrecht, The Netherlands

  3. 3

    GlaxoSmithKline, Research and Development, Stockley Park, UK

  1. †

    The authors Maarten van den Berge and Bart Luijk have contributed equally to this manuscript.

*M. van den Berge, Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, the Netherlands. Tel.: 31 50 3613532 Fax: 31 50 3619320 E-mail: m.van.den.berge@int.umcg.nl

  1. †

    The authors Maarten van den Berge and Bart Luijk have contributed equally to this manuscript.

  2. Edited by: Marek Sanak

Publication History

  1. Issue published online: 29 OCT 2010
  2. Article first published online: 29 OCT 2010
  3. Accepted for publication 15 April 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

Keywords:

  • adenosine 5′-monophosphate;
  • airway hyperresponsiveness;
  • asthma;
  • eNO;
  • fluticasone furoate;
  • fluticasone propionate

To cite this article: van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, Lammers J-WJ. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010; 65: 1531–1535.

Abstract

Introduction:  Single-dose inhaled corticosteroids (ICS) induce direct anti-inflammatory effects in asthma thereby improving airway hyperresponsiveness (AHR). A novel enhanced-affinity ICS, fluticasone furoate (FF), demonstrated a prolonged duration of action in vitro. The aim of this study was to evaluate the efficacy and duration of action of a single dose of FF by studying protection against AHR to adenosine 5′-monophosphate (AMP) and effects on exhaled nitric oxide (eNO).

Methods:  A randomized, double-blind, placebo-controlled, 6-way crossover study (FFA10026) was performed in 24 patients with allergic asthma (mean age 32.8 years, FEV1 ≥ 70% predicted and PC20 AMP ≤ 50 mg/ml). Each subject received a single dose of FF 1000 μg, fluticasone proprionate (FP) 1000 μg, or placebo at 2 (FF only), 14 or 26 h prior to AMP challenge and eNO measurement.

Results:  FF significantly improved PC20 AMP compared to placebo, the difference in doubling concentrations being 2.18 (95% confidence interval: 1.13–3.23), 1.54 (0.48–2.59), and 1.30 (0.26–2.34) at 2, 14 and 26 h. FP improved PC20 AMP significantly at 14 h compared to placebo, but not at the 26-hour time point, the difference in doubling concentrations being 1.72 (0.70–2.75) and 0.33 (−0.69–1.34). There was no significant effect on eNO after either FF or FP at all time points. FF was well tolerated and there were no serious adverse events.

Conclusion:  The new inhaled corticosteroid FF, but not FP, demonstrates prolonged protection up to 26 h against AHR to AMP in asthma patients.

View Full Article (HTML) Get PDF (152K)